TR200000654T2 - KAY-Yeni bir bağışıklık sistemi proteini. - Google Patents

KAY-Yeni bir bağışıklık sistemi proteini.

Info

Publication number
TR200000654T2
TR200000654T2 TR2000/00654T TR200000654T TR200000654T2 TR 200000654 T2 TR200000654 T2 TR 200000654T2 TR 2000/00654 T TR2000/00654 T TR 2000/00654T TR 200000654 T TR200000654 T TR 200000654T TR 200000654 T2 TR200000654 T2 TR 200000654T2
Authority
TR
Turkey
Prior art keywords
kay
immune system
system protein
new immune
new
Prior art date
Application number
TR2000/00654T
Other languages
English (en)
Turkish (tr)
Inventor
Tschopp Jurg
Original Assignee
Apotech R & D Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech R & D Sa filed Critical Apotech R & D Sa
Publication of TR200000654T2 publication Critical patent/TR200000654T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TR2000/00654T 1997-09-12 1998-09-11 KAY-Yeni bir bağışıklık sistemi proteini. TR200000654T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12

Publications (1)

Publication Number Publication Date
TR200000654T2 true TR200000654T2 (tr) 2000-07-21

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00654T TR200000654T2 (tr) 1997-09-12 1998-09-11 KAY-Yeni bir bağışıklık sistemi proteini.

Country Status (17)

Country Link
EP (1) EP1012270A2 (fr)
JP (1) JP2001515711A (fr)
KR (1) KR20010023892A (fr)
CN (1) CN1269832A (fr)
AU (1) AU9315298A (fr)
BR (1) BR9812433A (fr)
CA (1) CA2303424A1 (fr)
EA (1) EA200000311A1 (fr)
EE (1) EE200000148A (fr)
HU (1) HUP0004034A3 (fr)
IL (1) IL134480A0 (fr)
IS (1) IS5375A (fr)
NO (1) NO20001240L (fr)
PL (1) PL339740A1 (fr)
SK (1) SK3532000A3 (fr)
TR (1) TR200000654T2 (fr)
WO (1) WO1999012964A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
CA2310987A1 (fr) * 1997-11-26 1999-06-03 Eli Lilly And Company Gene de la famille des ligands du tnf
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
MXPA01007464A (es) 1999-01-25 2003-06-06 Apoxis Sa Baff, inhibidores del mismo y su uso en la modulacion de la respuesta de celula b.
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
NZ513290A (en) * 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2000068378A1 (fr) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Molecules d'acide nucleique, proteines et recepteurs tall-1, et procedes d'utilisation
KR20090016772A (ko) * 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001058949A2 (fr) 2000-02-11 2001-08-16 Biogen, Inc. Polypeptide heterologue de la famille tnf
JP5062606B2 (ja) 2000-02-16 2012-10-31 ジェネンテック， インコーポレイテッド Ｔｎｆ関連分子の活性を調節するためのアゴニスト及びアンタゴニストの使用
EP1280826B1 (fr) 2000-05-12 2007-05-02 Amgen Inc. Polypeptides pour inhibir l'activation des cellules b et t induite par april
DE60143798D1 (de) 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2001288260A1 (en) * 2000-08-15 2002-03-13 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
WO2002016411A2 (fr) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Polypeptides de fixation et procedes associes
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP4516719B2 (ja) 2001-05-11 2010-08-04 アムジエン・インコーポレーテツド Ｔａｌｌ−１と結合するペプチド及び関連分子
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
EP1608730B1 (fr) 2003-03-28 2013-11-06 Biogen Idec MA Inc. Recepteurs baff tronques
AU2004256042A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. BlyS antagonists and uses thereof
KR20070001880A (ko) 2003-10-20 2007-01-04 바이오겐 아이덱 엠에이 인코포레이티드 Ｂαｆｆ 길항제를 위한 치료 섭생법
AU2004315198A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of BCMA and uses thereof
ZA200702335B (en) 2004-10-05 2009-05-27 Genentech Inc Method for treating vasculitis
NZ583905A (en) 2004-10-13 2011-12-22 Univ Washington Use of BAFF to Treat Sepsis
WO2006067210A1 (fr) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Polypeptides bcma et leurs utilisations
AU2006278229B2 (en) 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
WO2007019573A2 (fr) 2005-08-09 2007-02-15 Zymogenetics, Inc. Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
KR20090016707A (ko) 2006-05-15 2009-02-17 아레스 트레이딩 에스.에이. Ｔａｃｉ­ｉｇ 융합 분자를 사용하여 자가면역 질병을 치료하는 방법
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
CN102597268B (zh) 2009-09-03 2017-09-22 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
ES2667420T3 (es) 2013-02-05 2018-05-10 Engmab Sàrl Anticuerpos biespecíficos contra cd3epsilon y bcma
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6001094A (en) * 1993-02-03 1994-08-29 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
EP0939804B2 (fr) * 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (fr) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf

Also Published As

Publication number Publication date
JP2001515711A (ja) 2001-09-25
BR9812433A (pt) 2000-09-26
CN1269832A (zh) 2000-10-11
AU9315298A (en) 1999-03-29
HUP0004034A3 (en) 2002-08-28
IS5375A (is) 2000-02-11
EP1012270A2 (fr) 2000-06-28
EA200000311A1 (ru) 2000-10-30
KR20010023892A (ko) 2001-03-26
WO1999012964A3 (fr) 1999-05-27
PL339740A1 (en) 2001-01-02
IL134480A0 (en) 2001-04-30
CA2303424A1 (fr) 1999-03-18
NO20001240D0 (no) 2000-03-09
NO20001240L (no) 2000-05-10
HUP0004034A2 (en) 2001-03-28
SK3532000A3 (en) 2001-12-03
EE200000148A (et) 2001-02-15
WO1999012964A2 (fr) 1999-03-18

Similar Documents

Publication Publication Date Title
TR200000654T2 (tr) KAY-Yeni bir bağışıklık sistemi proteini.
TR199900903T2 (xx) Bir t�m�r nekroz fakt�r� ailesine ili�kin protein
WO1999012965A3 (fr) Nouveaux ligands de la famille des tnf
FI861123L (fi) Kompression av bildelement i en videobild av reducerad storlek.
FI890420L (fi) Kompositpartikeldispersioner.
DE68919484D1 (de) Leuchtstofflampen-Armatur und -system.
WO1998057983A3 (fr) Proteine de mammifere de type facteur de croissance nerveuse
DE3582728D1 (de) Tertiaere aminoverbindungen.
ATE285474T1 (de) Haemophilus adhäsionsproteinen
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
DE3689144D1 (de) Pseudorabiesvirus-Protein.
FI943218A7 (fi) Kaseinomakropeptidin peptidit, mainittujen peptidien vasta-aineet ja k äytöt
NO892948L (no) Modifiserte proteiner.
FI971086A7 (fi) Kinaasia sitova proteiini ja sen käyttö
DE58905961D1 (de) Ultrazentrifuge zur Bestimmung von Teilchengrössenverteilungen.
BG103627A (en) New ifn receptor 1-binding proteins, dna encoding them, and methods for the modulation of a cellular response for interferons
FR2747681B1 (fr) Complexe proteique dodecaedrique adenoviral, composition le contenant et ses applications
KR930017721U (ko) 110v, 220v 겸용 전기밥솥
ATE55995T1 (de) Hydroxy- und alkoxypyrimidine.
IT8332310V0 (it) Impianto monoblocco di potabilizzazione.
FI853738A7 (fi) Partikkelilajittelija.
ES1009481Y (es) Nuevo plafon publicitario.